{"entity":{"type":"insider","cik":"0001598549","url":"/insider/0001598549","json_url":"/insider/0001598549.json","name":"Schwab Andrew J.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":180,"n_filings":68,"first":"2014-09-25","last":"2026-08-21","span_basis":"filed_date"},"name_variants":[{"name":"Schwab Andrew J.","source":"filing","n_filings":68,"first_seen":"2014-09-25","last_seen":"2026-08-21"}],"transactions":[{"id":9300323,"accession":"0001598549-26-000007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001598549-26-000007","line_url":"/filing/0001598549-26-000007#line-3","is_derivative":false,"issuer_cik":"0001736730","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001736730","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32018.0,"shares_display":"32,018","price_per_share":4.5,"price_display":"4.50","price_state":"stated","total_value":144081.0,"total_display":"144,081.00","total_whole":"144,081","shares_owned_after":2433280.0,"shares_owned_after_display":"2,433,280","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-21","filed_date":"2026-08-21","scope":"insider"},{"id":9300324,"accession":"0001598549-26-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001598549-26-000007","line_url":"/filing/0001598549-26-000007#line-2","is_derivative":false,"issuer_cik":"0001736730","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001736730","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114700.0,"shares_display":"114,700","price_per_share":4.54,"price_display":"4.54","price_state":"stated","total_value":520738.0,"total_display":"520,738.00","total_whole":"520,738","shares_owned_after":2465298.0,"shares_owned_after_display":"2,465,298","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-21","scope":"insider"},{"id":9299525,"accession":"0001598549-26-000005","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001598549-26-000005","line_url":"/filing/0001598549-26-000005","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7700.0,"shares_display":"7,700","price_per_share":0.32,"price_display":"0.32","price_state":"stated","total_value":2464.0,"total_display":"2,464.00","total_whole":"2,464","shares_owned_after":7850155.0,"shares_owned_after_display":"7,850,155","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-20","scope":"insider","n_lines":3},{"id":9300325,"accession":"0001598549-26-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001598549-26-000007","line_url":"/filing/0001598549-26-000007#line-1","is_derivative":false,"issuer_cik":"0001736730","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001736730","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":45147.0,"shares_display":"45,147","price_per_share":4.76,"price_display":"4.76","price_state":"stated","total_value":214899.72,"total_display":"214,899.72","total_whole":"214,900","shares_owned_after":2579998.0,"shares_owned_after_display":"2,579,998","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-21","scope":"insider"},{"id":9299522,"accession":"0001598549-26-000005","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001598549-26-000005","line_url":"/filing/0001598549-26-000005","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":68140.0,"shares_display":"68,140","price_per_share":0.35,"price_display":"0.35","price_state":"stated","total_value":23849.0,"total_display":"23,849.00","total_whole":"23,849","shares_owned_after":7856650.0,"shares_owned_after_display":"7,856,650","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-20","scope":"insider","n_lines":3},{"id":9299519,"accession":"0001598549-26-000005","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001598549-26-000005","line_url":"/filing/0001598549-26-000005","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300000.0,"shares_display":"300,000","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":114000.0,"total_display":"114,000.00","total_whole":"114,000","shares_owned_after":7914126.0,"shares_owned_after_display":"7,914,126","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-20","scope":"insider","n_lines":3},{"id":9276041,"accession":"0001231919-26-000854","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000854","line_url":"/filing/0001231919-26-000854#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52317.0,"shares_display":"52,317","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":358371.45,"total_display":"358,371.45","total_whole":"358,371","shares_owned_after":2783781.0,"shares_owned_after_display":"2,783,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-07","filed_date":"2026-08-10","scope":"insider"},{"id":9276042,"accession":"0001231919-26-000854","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000854","line_url":"/filing/0001231919-26-000854#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10494.0,"shares_display":"10,494","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":73458.0,"total_display":"73,458.00","total_whole":"73,458","shares_owned_after":2836098.0,"shares_owned_after_display":"2,836,098","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-06","filed_date":"2026-08-10","scope":"insider"},{"id":6042474,"accession":"0001231919-26-000822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000822","line_url":"/filing/0001231919-26-000822#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1718.0,"shares_display":"1,718","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":11768.3,"total_display":"11,768.30","total_whole":"11,768","shares_owned_after":2846592.0,"shares_owned_after_display":"2,846,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-31","filed_date":"2026-08-03","scope":"insider"},{"id":6042470,"accession":"0001231919-26-000822","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000822","line_url":"/filing/0001231919-26-000822#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114756.0,"shares_display":"114,756","price_per_share":6.93,"price_display":"6.93","price_state":"stated","total_value":795259.08,"total_display":"795,259.08","total_whole":"795,259","shares_owned_after":2848310.0,"shares_owned_after_display":"2,848,310","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-30","filed_date":"2026-08-03","scope":"insider"},{"id":5120377,"accession":"0001231919-25-000522","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000522","line_url":"/filing/0001231919-25-000522#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; Schwab Andrew J.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":8.8,"price_display":"8.80","price_state":"stated","total_value":1760000.0,"total_display":"1,760,000.00","total_whole":"1,760,000","shares_owned_after":2963066.0,"shares_owned_after_display":"2,963,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-14","filed_date":"2025-11-18","scope":"insider"},{"id":4320568,"accession":"0001415889-25-022808","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-022808","line_url":"/filing/0001415889-25-022808","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":170449.0,"shares_display":"170,449","price_per_share":3.42,"price_display":"3.42","price_state":"stated","total_value":582935.58,"total_display":"582,935.58","total_whole":"582,936","shares_owned_after":1457064.0,"shares_owned_after_display":"1,457,064","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-22","scope":"insider","n_lines":2},{"id":4320560,"accession":"0001415889-25-022808","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022808","line_url":"/filing/0001415889-25-022808","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60956.0,"shares_display":"60,956","price_per_share":3.57,"price_display":"3.57","price_state":"stated","total_value":217612.92,"total_display":"217,612.92","total_whole":"217,613","shares_owned_after":1621043.0,"shares_owned_after_display":"1,621,043","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-21","filed_date":"2025-08-22","scope":"insider","n_lines":2},{"id":4953009,"accession":"0001415889-25-019677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-019677","line_url":"/filing/0001415889-25-019677","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27000.0,"shares_display":"27,000","price_per_share":7.502,"price_display":"7.50","price_state":"stated","total_value":202554.0,"total_display":"202,554.00","total_whole":"202,554","shares_owned_after":3163066.0,"shares_owned_after_display":"3,163,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-09","filed_date":"2025-07-11","scope":"insider","n_lines":2},{"id":4320273,"accession":"0001415889-25-018822","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.1226,"price_display":"7.12","price_state":"stated","total_value":178065.0,"total_display":"178,065.00","total_whole":"178,065","shares_owned_after":3183131.0,"shares_owned_after_display":"3,183,131","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-01","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4320263,"accession":"0001415889-25-018822","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":6.8127,"price_display":"6.81","price_state":"stated","total_value":170317.5,"total_display":"170,317.50","total_whole":"170,318","shares_owned_after":3201709.0,"shares_owned_after_display":"3,201,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4320250,"accession":"0001415889-25-018822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75000.0,"shares_display":"75,000","price_per_share":6.91,"price_display":"6.91","price_state":"stated","total_value":518250.0,"total_display":"518,250.00","total_whole":"518,250","shares_owned_after":3220287.0,"shares_owned_after_display":"3,220,287","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":2354202,"accession":"0001104659-24-108702","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-24-108702","line_url":"/filing/0001104659-24-108702#line-4","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":2625145.0,"shares_owned_after_display":"2,625,145","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-15","scope":"insider"},{"id":2530713,"accession":"0001415889-24-023401","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-023401","line_url":"/filing/0001415889-24-023401","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13837.0,"shares_display":"13,837","price_per_share":6.06,"price_display":"6.06","price_state":"stated","total_value":83852.22,"total_display":"83,852.22","total_whole":"83,852","shares_owned_after":8167206.0,"shares_owned_after_display":"8,167,206","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-13","scope":"insider","n_lines":3},{"id":2530706,"accession":"0001415889-24-023401","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-023401","line_url":"/filing/0001415889-24-023401","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":"0001598549","owner_name":"Schwab Andrew J.","owner_display_name":"Schwab Andrew J.","owner_url":"/insider/0001598549","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":252500.0,"shares_display":"252,500","price_per_share":6.6,"price_display":"6.60","price_state":"stated","total_value":1666500.0,"total_display":"1,666,500.00","total_whole":"1,666,500","shares_owned_after":8178964.0,"shares_owned_after_display":"8,178,964","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-13","scope":"insider","n_lines":3},{"id":2070304,"accession":"0001415889-24-020035","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-020035","line_url":"/filing/0001415889-24-020035#line-4","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Opportunities II (GP), LLC; PARMAR KUSH; 5AM Opportunities II, L.P.; 5AM Ventures VI, L.P.","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":833333.0,"shares_display":"833,333","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":9999996.0,"total_display":"9,999,996.00","total_whole":"9,999,996","shares_owned_after":1182054.0,"shares_owned_after_display":"1,182,054","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-22","filed_date":"2024-07-24","scope":"insider"},{"id":3251890,"accession":"0001415889-24-004111","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004111","line_url":"/filing/0001415889-24-004111","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Opportunities I, L.P.; PARMAR KUSH; 5AM Ventures VI, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":825000.0,"shares_display":"825,000","price_per_share":14.9,"price_display":"14.90","price_state":"stated","total_value":12292500.0,"total_display":"12,292,500.00","total_whole":"12,292,500","shares_owned_after":3200634.0,"shares_owned_after_display":"3,200,634","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-16","scope":"insider","n_lines":2},{"id":2658941,"accession":"0001415889-24-002295","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002295","line_url":"/filing/0001415889-24-002295","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Ventures VI, L.P.; PARMAR KUSH; 5AM Opportunities I, L.P.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":3888992.0,"shares_owned_after_display":"3,888,992","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-02-02","scope":"insider","n_lines":2},{"id":8681058,"accession":"0001209191-23-050731","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-050731","line_url":"/filing/0001209191-23-050731","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Ventures VI, L.P.; Schwab Andrew J.; 5AM Partners VI, LLC; PARMAR KUSH; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"5AM Ventures VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":197500.0,"shares_display":"197,500","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2962500.0,"total_display":"2,962,500.00","total_whole":"2,962,500","shares_owned_after":4306179.0,"shares_owned_after_display":"4,306,179","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-26","filed_date":"2023-09-28","scope":"insider","n_lines":2},{"id":8043975,"accession":"0001209191-23-047514","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-047514","line_url":"/filing/0001209191-23-047514","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Ventures VI, L.P.; 5AM Partners VI, LLC; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; PARMAR KUSH; 5AM Opportunities I, L.P.","owner_display_name":"5AM Ventures VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":440000.0,"shares_display":"440,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":7040000.0,"total_display":"7,040,000.00","total_whole":"7,040,000","shares_owned_after":4470968.0,"shares_owned_after_display":"4,470,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-24","filed_date":"2023-08-28","scope":"insider","n_lines":2},{"id":8219916,"accession":"0001209191-23-024105","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-024105","line_url":"/filing/0001209191-23-024105","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Co-Investors IV, L.P.; ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; 5AM Partners IV, LLC; DIEKMAN JOHN D; Schwab Andrew J.; 5AM Ventures IV, L.P.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16544113.0,"shares_display":"16,544,113","price_per_share":0.12,"price_display":"0.12","price_state":"stated","total_value":1985293.56,"total_display":"1,985,293.56","total_whole":"1,985,294","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-10","filed_date":"2023-04-12","scope":"insider","n_lines":3},{"id":7897039,"accession":"0001209191-23-017533","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-017533","line_url":"/filing/0001209191-23-017533#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Partners V, LLC; ROCKLAGE SCOTT M; 5AM Ventures V, L.P.; Schwab Andrew J.","owner_display_name":"5AM Partners V, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":8.2,"price_display":"8.20","price_state":"stated","total_value":820000.0,"total_display":"820,000.00","total_whole":"820,000","shares_owned_after":2378969.0,"shares_owned_after_display":"2,378,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-07","filed_date":"2023-03-09","scope":"insider"},{"id":6457937,"accession":"0001209191-22-057195","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-057195","line_url":"/filing/0001209191-22-057195#line-6","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Partners IV, LLC; Schwab Andrew J.; 5AM Ventures IV, L.P.; DIEKMAN JOHN D; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61222.0,"shares_display":"61,222","price_per_share":2.52,"price_display":"2.52","price_state":"stated","total_value":154279.44,"total_display":"154,279.44","total_whole":"154,279","shares_owned_after":12836489.0,"shares_owned_after_display":"12,836,489","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-15","filed_date":"2022-11-15","scope":"insider"}],"collapsed":true,"next_cursor":"2022-11-15|6457937","ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":22,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001736730","name":"Camp4 Therapeutics Corp","url":"/issuer/0001736730","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2024-10-15","last_seen":"2026-08-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001516551","name":"Skye Bioscience, Inc.","url":"/issuer/0001516551","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2024-09-13","last_seen":"2026-08-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001689375","name":"Entrada Therapeutics, Inc.","url":"/issuer/0001689375","role":"Ten percent owner","n_filings":6,"first_seen":"2021-11-04","last_seen":"2026-08-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001817241","name":"Artiva Biotherapeutics, Inc.","url":"/issuer/0001817241","role":"Ten percent owner","n_filings":1,"first_seen":"2024-07-24","last_seen":"2024-07-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001672619","name":"Enliven Therapeutics, Inc.","url":"/issuer/0001672619","role":"Ten percent owner","n_filings":4,"first_seen":"2023-08-28","last_seen":"2024-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001835567","name":"Pear Therapeutics, Inc.","url":"/issuer/0001835567","role":"Ten percent owner","n_filings":6,"first_seen":"2022-08-18","last_seen":"2023-04-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001739410","name":"Rallybio Corp","url":"/issuer/0001739410","role":"Ten percent owner","n_filings":5,"first_seen":"2021-08-04","last_seen":"2023-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001604950","name":"scPharmaceuticals Inc.","url":"/issuer/0001604950","role":"Ten percent owner","n_filings":5,"first_seen":"2017-11-21","last_seen":"2022-10-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001868734","name":"CinCor Pharma, Inc.","url":"/issuer/0001868734","role":"Ten percent owner","n_filings":2,"first_seen":"2022-01-13","last_seen":"2022-08-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001817229","name":"Vor Biopharma Inc.","url":"/issuer/0001817229","role":"Ten percent owner","n_filings":2,"first_seen":"2021-02-09","last_seen":"2021-11-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001759138","name":"Cabaletta Bio, Inc.","url":"/issuer/0001759138","role":"Ten percent owner","n_filings":5,"first_seen":"2019-10-31","last_seen":"2021-11-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001445499","name":"IMPEL NEUROPHARMA INC","url":"/issuer/0001445499","role":"Ten percent owner","n_filings":1,"first_seen":"2021-04-29","last_seen":"2021-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001722271","name":"Akouos, Inc.","url":"/issuer/0001722271","role":"Ten percent owner","n_filings":2,"first_seen":"2020-07-02","last_seen":"2020-12-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001661998","name":"Homology Medicines, Inc.","url":"/issuer/0001661998","role":"Ten percent owner","n_filings":6,"first_seen":"2018-11-20","last_seen":"2020-12-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001676725","name":"IDEAYA Biosciences, Inc.","url":"/issuer/0001676725","role":"Ten percent owner","n_filings":2,"first_seen":"2019-05-28","last_seen":"2020-11-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001781983","name":"Aprea Therapeutics, Inc.","url":"/issuer/0001781983","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2019-10-09","last_seen":"2020-10-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001655759","name":"ARVINAS, INC.","url":"/issuer/0001655759","role":"Ten percent owner","n_filings":3,"first_seen":"2019-04-01","last_seen":"2019-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001658247","name":"Crinetics Pharmaceuticals, Inc.","url":"/issuer/0001658247","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2018-07-20","last_seen":"2019-06-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001628738","name":"Audentes Therapeutics, Inc.","url":"/issuer/0001628738","role":"Other","n_filings":1,"first_seen":"2017-04-26","last_seen":"2017-04-26"},{"type":"issuer","type_label":"ISSUER","cik":"0000879682","name":"VIVEVE MEDICAL, INC.","url":"/issuer/0000879682","role":"Ten percent owner","n_filings":2,"first_seen":"2014-09-25","last_seen":"2015-05-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001135906","name":"EPIRUS Biopharmaceuticals, Inc.","url":"/issuer/0001135906","role":"Ten percent owner","n_filings":1,"first_seen":"2015-02-06","last_seen":"2015-02-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001598549","retrieved_at":"2026-08-23T02:05:13+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}